Quoin Shares Corporate Update, Positive Clinical Data and Q3 Financial Results

Company’s global network now spans 61 countries In today’s corporate update, Quoin Pharmaceuticals (Nasdaq: QNRX) CEO, Dr. Michael Myers, shared the company’s “significant progress across multiple fronts culminating in the release of additional positive clinical data” for QRX003 in its ongoing Netherton Syndrome clinical trial. Subjects reported reduction in itching, improved skin appearance and satisfaction…